NCI NCTN-Network Lead Academic Site at UPCI
NCI NCTN-Network Lead Academic Site at UPCI
批准号:
9024474
负责人:
ADAM M BRUFSKY
金额:
$85.35万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-24 至 2019-02-28
关键词:
AccountingAffectAmericanAmerican College of Surgeons Oncology GroupBasic ScienceCancer BurdenCaringCause of DeathCessation of lifeClinical ResearchClinical TreatmentClinical TrialsClinical Trials Cooperative GroupCommunity Clinical Oncology ProgramComprehensive Cancer CenterConduct Clinical TrialsCooperative Group ProgramDetectionDevelopmentDiagnosisEarly DiagnosisEarly treatmentEastern Cooperative Oncology GroupEducationExpenditureFundingFutureGynecologic Oncology GroupHeart DiseasesInstitute of Medicine (U.S.)InstitutionLeadLeadershipMalignant NeoplasmsMedicalMulti-Institutional Clinical TrialNational Clinical Trials NetworkNational Surgical Adjuvant Breast and Bowel ProjectPennsylvaniaPhysiciansPositioning AttributePreventionProcessProgress ReportsPublic HealthRadiation Therapy Oncology GroupRecommendationResearch InfrastructureResearch PersonnelScienceSiteSurvival RateTranslational ResearchUnited StatesUniversity of Pittsburgh Cancer Institutebasecancer carecancer clinical trialcancer diagnosiscancer therapycostimprovednext generationprogramspublic health relevancesoundtreatment trialtrend
中文摘要
描述(由申请人提供):50多年来,NCI一直支持临床试验基础设施[NCI国家临床试验合作小组计划(CTCGP)],以在全国范围内进行大规模的临床治疗试验。作为其努力的一部分
为了利用肿瘤科学的新发现,NCI在2009年要求医学研究所(LOM)审查NCI赞助的CTCGP。根据LOM审查建议,以及从肿瘤学社区的利益相关者那里收到的额外信息,NCI制定了一项全面的计划,将以前资助几个独立组织进行癌症治疗试验的CTCGP转变为一个新的合并和综合计划,称为NCI国家临床试验网络(NCTN)。匹兹堡大学癌症研究所(UPCI)自1990年以来一直是NCI指定的综合癌症中心。UPCI干练地领导并参与了几个NCI CTCGP,包括ECOG、NSABP、RTOG、GOG和ACOSOG。UPCI现在计划参与新的NCI NCTN,作为一个主要的学术站点。我们建议参加NCTN作为一个网络领先的学术参与网站,具体目标如下:1.在整个NCTN的临床试验的开发和进行中,提高科学和行政领导的质量;2.继续并提高我们对多中心临床试验的收益
继续和改进快速启动UPCI新试验的流程。
英文摘要
DESCRIPTION (provided by applicant): For more than 50 years, the NCI has supported a clinical trials infrastructure [the NCI National Clinical Trials Cooperative Group Program (CTCGP)] to conduct large-scale, clinical treatment trials across the nation. As part of its effort
to take advantage of new discoveries in oncologic sciences, the NCI asked the Institute of Medicine (lOM) in 2009 to review the NCI-sponsored CTCGP. Based on the lOM review recommendations, as well as additional input received from stakeholders across the oncology community, the NCI has developed a comprehensive plan to transform the previous CTCGP that funded several separate organizations conducting cancer treatment trials into a new consolidated and integrated Program referred to as the NCI National Clinical Trials Network (NCTN). The University of Pittsburgh Cancer Institute (UPCI) has been an NCI-designated Comprehensive Cancer Center since 1990. The UPCI has led ably and participated in several NCI CTCGPs, including ECOG, NSABP, RTOG, GOG, and ACOSOG. The UPCI now plans to participate under the new NCI NCTN as a Lead Academic Site. We propose to participate in NCTN as a Network Lead Academic Participating Site with the following Specific Aims: 1. To enhance the quality off scientific and administrative leadership in the development and conduct of clinical trials across the NCTN; 2. To continue and improve our accrual to multi-center clinical
trials at UPCI; To continue and improve processes for rapid activation of new trials at UPCI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
-
批准号:10733571
-
项目类别:
-
资助金额:$4.0万
-
财政年份:2022
-
负责人:ADAM M BRUFSKY
-
依托单位:
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
-
批准号:10116973
-
项目类别:
-
资助金额:$91.11万
-
财政年份:2019
-
负责人:ADAM M BRUFSKY
-
依托单位:
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
-
批准号:10582598
-
项目类别:
-
资助金额:$91.11万
-
财政年份:2019
-
负责人:ADAM M BRUFSKY
-
依托单位:
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
-
批准号:10359765
-
项目类别:
-
资助金额:$91.11万
-
财政年份:2019
-
负责人:ADAM M BRUFSKY
-
依托单位:
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
-
批准号:9923609
-
项目类别:
-
资助金额:$91.11万
-
财政年份:2019
-
负责人:ADAM M BRUFSKY
-
依托单位:
NCI NCTN-Network Lead Academic Site at UPCI
-
批准号:8605956
-
项目类别:
-
资助金额:$94.57万
-
财政年份:2014
-
负责人:ADAM M BRUFSKY
-
依托单位:
RHUMABHER2/CYCLOPHOSPHAMIDE/DOXORUBICIN AND PLACEBO/CYCLOPHOSPHAMIDE/DOXORUCINB
-
批准号:6304687
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1999
-
负责人:ADAM M BRUFSKY
-
依托单位:
SAFETY STUDY OF RECOMBINANT MONOCLONAL ANTIBODY
-
批准号:6304653
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1999
-
负责人:ADAM M BRUFSKY
-
依托单位:
RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER
-
批准号:6304677
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1999
-
负责人:ADAM M BRUFSKY
-
依托单位:
RHUMABHER2/CYCLOPHOSPHAMIDE/DOXORUBICIN AND PLACEBO/CYCLOPHOSPHAMIDE/DOXORUCINB
-
批准号:6219253
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1998
-
负责人:ADAM M BRUFSKY
-
依托单位:
SAFETY STUDY OF RECOMBINANT MONOCLONAL ANTIBODY
-
批准号:6264180
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1998
-
负责人:ADAM M BRUFSKY
-
依托单位:
RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER
-
批准号:6219239
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1998
-
负责人:ADAM M BRUFSKY
-
依托单位:
LIPOSOMAL ANNAMYCIN IN TAXANE RESISTANT BREAST CANCER
-
批准号:6264179
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1998
-
负责人:ADAM M BRUFSKY
-
依托单位:
RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER
-
批准号:6275815
-
项目类别:
-
资助金额:$1.91万
-
财政年份:1997
-
负责人:ADAM M BRUFSKY
-
依托单位:
Cancer Therapeutics Program
-
批准号:10024353
-
项目类别:
-
资助金额:$5.68万
-
财政年份:1997
-
负责人:ADAM M BRUFSKY
-
依托单位:
Cancer Therapeutics Program
-
批准号:10254113
-
项目类别:
-
资助金额:$5.12万
-
财政年份:1997
-
负责人:ADAM M BRUFSKY
-
依托单位:
Cancer Therapeutics Program
-
批准号:10674880
-
项目类别:
-
资助金额:$5.77万
-
财政年份:1997
-
负责人:ADAM M BRUFSKY
-
依托单位:
RHUMABHER2/CYCLOPHOSPHAMIDE/DOXORUBICIN AND PLACEBO/CYCLOPHOSPHAMIDE/DOXORUCINB
-
批准号:6275829
-
项目类别:
-
资助金额:$1.91万
-
财政年份:1997
-
负责人:ADAM M BRUFSKY
-
依托单位:
Cancer Therapeutics Program
-
批准号:10474536
-
项目类别:
-
资助金额:$5.77万
-
财政年份:1997
-
负责人:ADAM M BRUFSKY
-
依托单位:
ANDROGEN RECEPTOR ASSOCIATED PROTEINS IN PROSTATE CANCER
-
批准号:2111821
-
项目类别:
-
资助金额:$7.66万
-
财政年份:1995
-
负责人:ADAM M BRUFSKY
-
依托单位:
海外基金